Halozyme Therapeutics Inc(HALO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:41 AM ET (Korea 9/11 20:41)
Full metrics table
| Index | - | P/E | 31.97 | EPS (ttm) | 3.35 | Insider Own | 1.05% | Shs Outstand | 114.0M | Perf Week | -2.43% |
| Market Cap | 12.14B | Forward P/E | 10.39 | EPS next Y | 22.39% | Insider Trans | -17.6% | Shs Float | 112.3M | Perf Month | 4.27% |
| Enterprise Value | 14.06B | PEG | 0.25 | EPS next Q | 2.25 | Inst Own | 109.79% | Short Float | 13.03% | Perf Quarter | 51.77% |
| Income | 0.41B | P/S | 7.3 | EPS this Y | 102.75% | Inst Trans | 0.58% | Short Ratio | 7.42 | Perf Half Y | 60.95% |
| Sales | 1.66B | P/B | 85.01 | EPS next 5Y | 41.35% | ROA | 17.86% | Short Interest | 14.64M | Perf YTD | 58.99% |
| Book/sh | 1.26 | P/C | 52.57 | EPS past 3/5Y | 21.17% 22.89% | ROE | 173.67% | 52W High | -3.73% ($111.15) | Perf Year | 41.16% |
| Cash/sh | 2.04 | P/FCF | 15.06 | Sales past 3/5Y | 28.38% 39.16% | ROIC | 19.87% | 52W Low | 74.77% ($61.22) | Perf 3Y | 177.85% |
| Dividend Est. | - | EV/EBITDA | 13.27 | EPS Y/Y TTM | -21.44% | Gross Margin | 76.4% | Volatility(W/M) | 2.79% 2.6% | Perf 5Y | 159.46% |
| Dividend TTM | - | EV/Sales | 8.45 | Sales Y/Y TTM | 41.15% | Oper. Margin | 56.77% | ATR (14) | 2.8 | Perf 10Y | 963.62% |
| Dividend Ex-Date | - | Quick Ratio | 2.31 | EPS Q/Q | 42.59% | Profit Margin | 24.86% | RSI (14) | 62.1 | Recom | 1.73 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.71 | Sales Q/Q | 47.67% | SMA20 | 0.28% ($106.7) | Beta | 0.88 | Target Price | $99.56 |
| Payout | - | Debt/Eq | 14.96 | Earnings | 2026/8/6 | SMA50 | 15.66% ($92.51) | Rel Volume | 0.65 | Prev Close | $107.39 |
| Employees | 423 | LT Debt/Eq | 13.5 | EPS/Sales Surpr. | 27.58% 19.57% | SMA200 | 43.09% ($74.78) | Avg Volume(3M) | 1.97M | Price | $107 |
| IPO | 2004/3/12 | Option/Short | Yes/Yes | Trades | 15650 | Volume | 1,282,686 | Change | -0.36% |
Company
HALO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A healthcare company that holds a drug delivery platform technology capable of converting intravenous (IV) biologics into subcutaneous injection formulations. The company operates a high-margin business model by licensing its proprietary enzyme-based technology to large pharmaceutical companies and collecting royalties from sales of partnered products.
Over the past 1 year, on the higher side
4% below its 1-year high.
HALO has weak earning power
56.77% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +102.8% this year.
Tap to view numbers
The price looks about right
Trading at 32.0 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +177.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 109.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
CTEF 0.04%
FFOX 0.03%
FBT 0.03%
SCAP 0.03%
PBE 0.03%It ranks #4 in the industry
Based on market cap of $12B.
HALO $12B PER 32.0
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is HALO?
HALO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HALO?
The market cap of HALO is approximately $12.1B, ranking 829 within its sector.
What is the P/E ratio of HALO?
HALO has a P/E ratio of approximately 32.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HALO?
HALO has recorded a 52-week high of $111.15 and a low of $61.22.
